Cargando…

Hydrochloride Salt of the GABAkine KRM-II-81

[Image: see text] Imidazodiazepine (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-α][1,4]diazepin-3-yl) oxazole or KRM-II-81) is a potentiator of GABA(A) receptors (a GABAkine) undergoing preparation for clinical development. KRM-II-81 is active against many seizure and pain models in roden...

Descripción completa

Detalles Bibliográficos
Autores principales: Mian, Md Yeunus, Divović, Branka, Sharmin, Dishary, Pandey, Kamal P., Golani, Lalit K., Tiruveedhula, V. V. N. Phani Babu, Cerne, Rok, Smith, Jodi L., Ping, Xingjie, Jin, Xiaoming, Imler, Gregory H., Deschamps, Jeffrey R., Lippa, Arnold, Cook, James M., Savić, Miroslav M., Rowlett, James, Witkin, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366947/
https://www.ncbi.nlm.nih.gov/pubmed/35967038
http://dx.doi.org/10.1021/acsomega.2c03029
_version_ 1784765679799369728
author Mian, Md Yeunus
Divović, Branka
Sharmin, Dishary
Pandey, Kamal P.
Golani, Lalit K.
Tiruveedhula, V. V. N. Phani Babu
Cerne, Rok
Smith, Jodi L.
Ping, Xingjie
Jin, Xiaoming
Imler, Gregory H.
Deschamps, Jeffrey R.
Lippa, Arnold
Cook, James M.
Savić, Miroslav M.
Rowlett, James
Witkin, Jeffrey M.
author_facet Mian, Md Yeunus
Divović, Branka
Sharmin, Dishary
Pandey, Kamal P.
Golani, Lalit K.
Tiruveedhula, V. V. N. Phani Babu
Cerne, Rok
Smith, Jodi L.
Ping, Xingjie
Jin, Xiaoming
Imler, Gregory H.
Deschamps, Jeffrey R.
Lippa, Arnold
Cook, James M.
Savić, Miroslav M.
Rowlett, James
Witkin, Jeffrey M.
author_sort Mian, Md Yeunus
collection PubMed
description [Image: see text] Imidazodiazepine (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-α][1,4]diazepin-3-yl) oxazole or KRM-II-81) is a potentiator of GABA(A) receptors (a GABAkine) undergoing preparation for clinical development. KRM-II-81 is active against many seizure and pain models in rodents, where it exhibits improved pharmacological properties over standard-of-care agents. Since salts can be utilized to create opportunities for increased solubility, enhanced absorption, and distribution, as well as for efficient methods of bulk synthesis, a hydrochloride salt of KRM-II-81 was prepared. KRM-II-81·HCl was produced from the free base with anhydrous hydrochloric acid. The formation of the monohydrochloride salt was confirmed by X-ray crystallography, as well as (1)H NMR and (13)C NMR analyses. High water solubility and a lower partition coefficient (octanol/water) were exhibited by KRM-II-81·HCl as compared to the free base. Oral administration of either KRM-II-81·HCl or the free base resulted in high concentrations in the brain and plasma of rats. Oral dosing in mice significantly increased the latency to both clonic and tonic convulsions and decreased pentylenetetrazol-induced lethality. The increased water solubility of the HCl salt enables intravenous dosing and the potential for higher concentration formulations compared with the free base without impacting anticonvulsant potency. Thus, KRM-II-81·HCl adds an important new compound to facilitate the development of these imidazodiazepines for clinical evaluation.
format Online
Article
Text
id pubmed-9366947
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-93669472022-08-12 Hydrochloride Salt of the GABAkine KRM-II-81 Mian, Md Yeunus Divović, Branka Sharmin, Dishary Pandey, Kamal P. Golani, Lalit K. Tiruveedhula, V. V. N. Phani Babu Cerne, Rok Smith, Jodi L. Ping, Xingjie Jin, Xiaoming Imler, Gregory H. Deschamps, Jeffrey R. Lippa, Arnold Cook, James M. Savić, Miroslav M. Rowlett, James Witkin, Jeffrey M. ACS Omega [Image: see text] Imidazodiazepine (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-α][1,4]diazepin-3-yl) oxazole or KRM-II-81) is a potentiator of GABA(A) receptors (a GABAkine) undergoing preparation for clinical development. KRM-II-81 is active against many seizure and pain models in rodents, where it exhibits improved pharmacological properties over standard-of-care agents. Since salts can be utilized to create opportunities for increased solubility, enhanced absorption, and distribution, as well as for efficient methods of bulk synthesis, a hydrochloride salt of KRM-II-81 was prepared. KRM-II-81·HCl was produced from the free base with anhydrous hydrochloric acid. The formation of the monohydrochloride salt was confirmed by X-ray crystallography, as well as (1)H NMR and (13)C NMR analyses. High water solubility and a lower partition coefficient (octanol/water) were exhibited by KRM-II-81·HCl as compared to the free base. Oral administration of either KRM-II-81·HCl or the free base resulted in high concentrations in the brain and plasma of rats. Oral dosing in mice significantly increased the latency to both clonic and tonic convulsions and decreased pentylenetetrazol-induced lethality. The increased water solubility of the HCl salt enables intravenous dosing and the potential for higher concentration formulations compared with the free base without impacting anticonvulsant potency. Thus, KRM-II-81·HCl adds an important new compound to facilitate the development of these imidazodiazepines for clinical evaluation. American Chemical Society 2022-07-27 /pmc/articles/PMC9366947/ /pubmed/35967038 http://dx.doi.org/10.1021/acsomega.2c03029 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Mian, Md Yeunus
Divović, Branka
Sharmin, Dishary
Pandey, Kamal P.
Golani, Lalit K.
Tiruveedhula, V. V. N. Phani Babu
Cerne, Rok
Smith, Jodi L.
Ping, Xingjie
Jin, Xiaoming
Imler, Gregory H.
Deschamps, Jeffrey R.
Lippa, Arnold
Cook, James M.
Savić, Miroslav M.
Rowlett, James
Witkin, Jeffrey M.
Hydrochloride Salt of the GABAkine KRM-II-81
title Hydrochloride Salt of the GABAkine KRM-II-81
title_full Hydrochloride Salt of the GABAkine KRM-II-81
title_fullStr Hydrochloride Salt of the GABAkine KRM-II-81
title_full_unstemmed Hydrochloride Salt of the GABAkine KRM-II-81
title_short Hydrochloride Salt of the GABAkine KRM-II-81
title_sort hydrochloride salt of the gabakine krm-ii-81
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366947/
https://www.ncbi.nlm.nih.gov/pubmed/35967038
http://dx.doi.org/10.1021/acsomega.2c03029
work_keys_str_mv AT mianmdyeunus hydrochloridesaltofthegabakinekrmii81
AT divovicbranka hydrochloridesaltofthegabakinekrmii81
AT sharmindishary hydrochloridesaltofthegabakinekrmii81
AT pandeykamalp hydrochloridesaltofthegabakinekrmii81
AT golanilalitk hydrochloridesaltofthegabakinekrmii81
AT tiruveedhulavvnphanibabu hydrochloridesaltofthegabakinekrmii81
AT cernerok hydrochloridesaltofthegabakinekrmii81
AT smithjodil hydrochloridesaltofthegabakinekrmii81
AT pingxingjie hydrochloridesaltofthegabakinekrmii81
AT jinxiaoming hydrochloridesaltofthegabakinekrmii81
AT imlergregoryh hydrochloridesaltofthegabakinekrmii81
AT deschampsjeffreyr hydrochloridesaltofthegabakinekrmii81
AT lippaarnold hydrochloridesaltofthegabakinekrmii81
AT cookjamesm hydrochloridesaltofthegabakinekrmii81
AT savicmiroslavm hydrochloridesaltofthegabakinekrmii81
AT rowlettjames hydrochloridesaltofthegabakinekrmii81
AT witkinjeffreym hydrochloridesaltofthegabakinekrmii81